Medtronic Pursues Minimally Invasive AF Treatment

 

November 10, 2006

Medtronic, Inc. has the FDA’s approval to initiate the Feasibility of the Lone Atrial Fibrillation Clinical Trial (FACT), which coincides with the launch of Medtronic’s Cardioblate Navigator Tissue Dissector.

The purpose of the FACT feasibility clinical trial is to evaluate the use of the Cardioblate Surgical Ablation System thorascopically in paroxysmal atrial fibrillation patients. The prospective, non-randomized, feasibility clinical trial will enroll 15 patients at three U.S. medical centers including Scott & White Memorial Hospital (Temple, TX), Beth Israel Hospital (Boston, MA), and LDS Hospital (Salt Lake City, UT). The primary endpoints of the trial are to evaluate the freedom of symptomatic paroxysmal AF episodes using Cardioblate surgical ablation devices in lone AF patients.

While none of the devices used in the trial are investigational, results of the trial will be used to design U.S. pivotal studies for an additional indication of use for the Cardioblate Surgical Ablation System in the U.S. to treat paroxysmal atrial fibrillation. The commercial release of the Navigator Tissue Dissector complements Medtronic’s Cardioblate family of bipolar solutions with technology for this stand-alone, surgical ablation procedure.

For further information visit www.medtronic.com.

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.